Rationale for the use of somatostatin analogs as antitumor agents
about
The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumorsNotch Signaling in Neuroendocrine TumorsThe effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegalyFrom targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumorsCirculating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlookNanoparticle ligand presentation for targeting solid tumorsClinical utility of lanreotide Autogel® in gastroenteropancreatic neuroendocrine tumorsSomatostatin receptor expression on von Hippel-Lindau-associated hemangioblastomas offers novel therapeutic target.New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.The somatostatin 2A receptor is enriched in migrating neurons during rat and human brain development and stimulates migration and axonal outgrowthPeptide-based probes for targeted molecular imaging.The antiproliferative effects of somatostatin receptor subtype 2 in breast cancer cells.Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic indexDesign and applications of bispecific heterodimers: molecular imaging and beyondPeptides and peptide hormones for molecular imaging and disease diagnosisTrial watch: Immunostimulatory cytokines in cancer therapy.The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets.Somatostatin derivative (smsDX) targets cellular metabolism in prostate cancer cells after androgen deprivation therapy.Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study.Expressions of Somatostatin Receptor Subtypes (SSTR-1, 2, 3, 4 and 5) in Neuroblastic Tumors; Special Reference to Clinicopathological Correlations with International Neuroblastoma Pathology Classification and Outcomes.Sustained-release delivery of octreotide from biodegradable polymeric microspheres.The effect of co-administration of Lawsonia inermis extract and octreotide on experimental hepatocellular carcinomaNotch1-mediated tumor suppression in cervical cancer with the involvement of SST signaling and its application in enhanced SSTR-targeted therapeutics.A rare gastric neuroendocrine carcinoma coexisting with Brunner's gland adenoma: A case report.Antitumor effects of somatostatin analogs in neuroendocrine tumors.Expression of Somatostatin Receptor (SSTR) Subtypes (SSTR-1, 2A, 3, 4 and 5) in Neuroendocrine Tumors Using Real-time RT-PCR Method and ImmunohistochemistryManagement of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program.The expanding role of somatostatin analogs in the management of neuroendocrine tumors.Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study.From somatostatin to octreotide LAR: evolution of a somatostatin analogueUpdate on management of midgut neuroendocrine tumors.New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapySomatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis B-related hepatocellular carcinoma following octreotide long-acting release treatment.Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survivalThrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer.The truncated isoform of somatostatin receptor5 (sst5TMD4) is associated with poorly differentiated thyroid cancer.Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology.Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology.Octreotide LAR: safety and tolerability issues.
P2860
Q26740374-0935F8C9-6C70-46E8-95E7-9F43260FB27DQ26752380-83D287D1-1A08-412D-82B3-E54973901AE4Q26796357-FF013975-0771-4DF4-BB7E-03681C265F98Q26822011-D8DE141E-03AB-4250-8CD2-7697F8E3B074Q26823035-9B5144CC-7DD3-4407-8094-9819F9B49899Q27009522-E139F2C6-5EA9-4327-BD32-7892FAD98C9AQ28069632-2134C743-1CD5-412D-8165-43E03F2B9085Q30274979-1AF13982-70C9-429C-A9EC-E8B5BB012DA9Q30364864-4EC954B2-EC91-4A6E-813B-4254736BEBD2Q33443929-A246D781-E754-4156-A3AB-E60AA2CA25D0Q33526620-2F7B1877-3EDD-4036-B255-75A247B3389EQ33552691-B0A605F8-2282-46F5-8705-9410CC3782BCQ33648996-26FFB61F-6639-40FB-BF92-1DAB541A2E00Q33718131-065600D9-28D7-4106-9DC5-E7456CC984EAQ33732587-22BA2FE9-6A85-465E-9B6B-F62789BE8111Q33846924-3745D9E4-B639-492A-966B-1A1F1093A45DQ33880165-1E228A9A-770B-4131-B517-1F6B6270D089Q34182483-75E2CF1F-A036-4A39-81F1-FF296BE46240Q34586300-82B9D7C4-E50F-45C0-9B76-DB4F50C14DBDQ34992833-F3D7E43C-5960-40B6-8E35-F8FBF0FA60DDQ35288725-3D088E67-CB8D-4DC2-B9F7-92F9919494D4Q35577254-4259EC9A-CE9D-422C-B9D8-91CDD1EFF997Q35614440-20EA8378-8DEC-416F-895D-194B04880987Q35776244-A92F3C9D-863B-4B54-9CDB-3C1279D38A68Q35944519-43589B47-3A1D-4CF7-A107-978592580945Q36051476-A0301C3B-9EEF-4865-AE76-28C9861FFBB9Q36090916-5D153C0E-4610-432B-8DC5-52825D14EC25Q36184629-FF56672B-12DA-4001-8642-B3EB65ADA816Q36347272-FBA1B26A-767D-43ED-948F-E825457BDE0BQ36565634-B307EC70-64C6-4A45-9EA9-B7C9B3173320Q36919554-09E8B5EB-83AC-44BA-8008-2BC6A0000361Q37025143-DF3AA15B-44DD-4D3E-98A6-13AF3BDE3F01Q37049132-008B9391-442B-43CD-8821-FF031577CE77Q37211764-34262C47-9C14-482E-9CFF-766BDC197770Q37326199-71EFF542-4D4B-48D7-9511-3FAEA7C83C51Q37394454-5E35792D-D42B-4CEC-B08F-B045936FD0F6Q37499468-0A867449-CD50-4480-937D-C82F1487A2DAQ37579225-BFB4F7B4-F0DA-4C28-A7D7-18DBAAA281F9Q37634917-F6E44BE0-A169-4197-BC22-64846C38E878Q37649647-4D4AAD31-A856-4574-A75B-41B8858CA65E
P2860
Rationale for the use of somatostatin analogs as antitumor agents
description
2006 nî lūn-bûn
@nan
2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Rationale for the use of somatostatin analogs as antitumor agents
@ast
Rationale for the use of somatostatin analogs as antitumor agents
@en
Rationale for the use of somatostatin analogs as antitumor agents
@nl
type
label
Rationale for the use of somatostatin analogs as antitumor agents
@ast
Rationale for the use of somatostatin analogs as antitumor agents
@en
Rationale for the use of somatostatin analogs as antitumor agents
@nl
prefLabel
Rationale for the use of somatostatin analogs as antitumor agents
@ast
Rationale for the use of somatostatin analogs as antitumor agents
@en
Rationale for the use of somatostatin analogs as antitumor agents
@nl
P3181
P356
P1433
P1476
Rationale for the use of somatostatin analogs as antitumor agents
@en
P2093
P304
P3181
P356
10.1093/ANNONC/MDL105
P407
P577
2006-12-01T00:00:00Z